These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 1553573

  • 21. Effects of mast cell growth factor on Ara-C mediated acute myeloid leukemia cell killing.
    Tafuri A, De Felice L, Mascolo MG, Valentini T, Petrucci MT, Petti MC.
    Stem Cells; 1993 Jul; 11 Suppl 2():88-92. PubMed ID: 7691332
    [Abstract] [Full Text] [Related]

  • 22. Enhancement of cytosine arabinoside cytotoxicity by granulocyte/macrophage colony-stimulating factor and granulocyte colony-stimulating factor in a human myeloblastic leukemia cell line.
    Takauji R, Tohyama K, Ueda T, Nakamura T.
    Jpn J Cancer Res; 1993 Apr; 84(4):445-50. PubMed ID: 7685751
    [Abstract] [Full Text] [Related]

  • 23. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs.
    Tafuri A, Lemoli RM, Chen R, Gulati SC, Clarkson BD, Andreeff M.
    Leukemia; 1994 May; 8(5):749-57. PubMed ID: 7514244
    [Abstract] [Full Text] [Related]

  • 24. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
    Braess J, Wegendt C, Jahns-Streubel G, Kern W, Keye S, Unterhalt M, Schleyer E, Hiddemann W.
    Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
    [Abstract] [Full Text] [Related]

  • 25. Colony-stimulating factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside.
    Andreeff M, Tafuri A, Hegewisch-Becker S.
    Haematol Blood Transfus; 1990 May; 33():747-62. PubMed ID: 2323674
    [Abstract] [Full Text] [Related]

  • 26. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside.
    Yang GS, Minden MD, McCulloch EA.
    Leukemia; 1993 Jul; 7(7):1012-9. PubMed ID: 7686602
    [Abstract] [Full Text] [Related]

  • 27. Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells.
    Van Der Lely N, De Witte T, Muus P, Raymakers R, Preijers F, Haanen C.
    Exp Hematol; 1991 May; 19(4):267-72. PubMed ID: 2055291
    [Abstract] [Full Text] [Related]

  • 28. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
    Estrov Z, Estey EH, Andreeff M, Talpaz M, Kurzrock R, Reading CL, Deisseroth AB, Gutterman JU.
    Exp Hematol; 1992 Jun; 20(5):558-64. PubMed ID: 1587302
    [Abstract] [Full Text] [Related]

  • 29. Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trial.
    Hiddemann W, Zühlsdorf M, Wörmann B, Koenigsmann M, Büchner T.
    Leuk Res; 1990 Jun; 14(4):347-52. PubMed ID: 2185381
    [Abstract] [Full Text] [Related]

  • 30. Myelosuppressive effects of cytosine arabinoside (Ara-C) on growth factor-dependent human long-term bone marrow cultures (LTBMC).
    Kalla P, Oster W, Seiler FR, Rüde E, Krumwieh D.
    Int J Cell Cloning; 1992 Jan; 10(1):54-62. PubMed ID: 1552225
    [Abstract] [Full Text] [Related]

  • 31. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
    Waga K, Furusawa S, Nagashima S, Saito K, Shishido H.
    Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
    [Abstract] [Full Text] [Related]

  • 32. Effects of mast cell growth factor on acute myeloid leukemia cells in vitro: effects of combinations with other cytokines.
    Budel LM, Delwel R, van Buitenen C, Hoogerbrugge H, Löwenberg B.
    Leukemia; 1993 Mar; 7(3):426-34. PubMed ID: 7680401
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Differential effect of interleukin 3 on the metabolism of high-dose cytosine arabinoside in normal versus leukemic human bone marrow cells.
    Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Safah H, Graham G.
    Exp Hematol; 1991 Aug; 19(7):669-73. PubMed ID: 1893953
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 38. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) enhances high-dose Ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells.
    Bhalla K, Tang C, Ibrado AM, Grant S, Tourkina E, Holladay C, Hughes M, Mahoney ME, Huang Y.
    Blood; 1992 Dec 01; 80(11):2883-90. PubMed ID: 1450413
    [Abstract] [Full Text] [Related]

  • 39. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 01; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 40. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
    Lemoli RM, Gulati SC.
    Stem Cells; 1993 Sep 01; 11(5):435-44. PubMed ID: 7694721
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.